Product Code: ETC13176705 | Publication Date: Apr 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | No. of Pages: 150 | No. of Figures: 55 | No. of Tables: 32 |
North America Vaccines Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 North America Vaccines Market Overview |
3.1 North America Regional Macro Economic Indicators |
3.2 North America Vaccines Market Revenues & Volume, 2021 & 2031F |
3.3 North America Vaccines Market - Industry Life Cycle |
3.4 North America Vaccines Market - Porter's Five Forces |
3.5 North America Vaccines Market Revenues & Volume Share, By Countries, 2021 & 2031F |
3.6 North America Vaccines Market Revenues & Volume Share, By Technology, 2021 & 2031F |
3.7 North America Vaccines Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.8 North America Vaccines Market Revenues & Volume Share, By Disease Indication, 2021 & 2031F |
3.9 North America Vaccines Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.10 North America Vaccines Market Revenues & Volume Share, By Patient Type, 2021 & 2031F |
4 North America Vaccines Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 North America Vaccines Market Trends |
6 North America Vaccines Market, 2021 - 2031 |
6.1 North America Vaccines Market, Revenues & Volume, By Technology, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 North America Vaccines Market, Revenues & Volume, By Conjugate vaccines, 2021 - 2031 |
6.1.3 North America Vaccines Market, Revenues & Volume, By Inactivated and subunit vaccines, 2021 - 2031 |
6.1.4 North America Vaccines Market, Revenues & Volume, By Live attenuated vaccines, 2021 - 2031 |
6.1.5 North America Vaccines Market, Revenues & Volume, By Recombinant vaccines, 2021 - 2031 |
6.1.6 North America Vaccines Market, Revenues & Volume, By Toxoid vaccines, 2021 - 2031 |
6.2 North America Vaccines Market, Revenues & Volume, By Type, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 North America Vaccines Market, Revenues & Volume, By Monovalent vaccines, 2021 - 2031 |
6.2.3 North America Vaccines Market, Revenues & Volume, By Multivalent vaccines, 2021 - 2031 |
6.3 North America Vaccines Market, Revenues & Volume, By Disease Indication, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 North America Vaccines Market, Revenues & Volume, By Pneumococcal disease, 2021 - 2031 |
6.3.3 North America Vaccines Market, Revenues & Volume, By DTP, 2021 - 2031 |
6.3.4 North America Vaccines Market, Revenues & Volume, By Influenza, 2021 - 2031 |
6.3.5 North America Vaccines Market, Revenues & Volume, By HPV, 2021 - 2031 |
6.3.6 North America Vaccines Market, Revenues & Volume, By Meningococcal disease, 2021 - 2031 |
6.3.7 North America Vaccines Market, Revenues & Volume, By Polio, 2021 - 2031 |
6.3.8 North America Vaccines Market, Revenues & Volume, By Rotavirus, 2021 - 2031 |
6.3.9 North America Vaccines Market, Revenues & Volume, By Other disease indications, 2021 - 2031 |
6.4 North America Vaccines Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
6.4.2 North America Vaccines Market, Revenues & Volume, By Intramuscular and subcutaneous administration, 2021 - 2031 |
6.4.3 North America Vaccines Market, Revenues & Volume, By Oral administration, 2021 - 2031 |
6.4.4 North America Vaccines Market, Revenues & Volume, By Other routes of administration, 2021 - 2031 |
6.5 North America Vaccines Market, Revenues & Volume, By Patient Type, 2021 - 2031 |
6.5.1 Overview & Analysis |
6.5.2 North America Vaccines Market, Revenues & Volume, By Pediatric patients, 2021 - 2031 |
6.5.3 North America Vaccines Market, Revenues & Volume, By Adult patients, 2021 - 2031 |
7 North America Vaccines Market, By Countries, 2021 - 2031 |
7.1 Overview & Analysis |
7.2 North America Vaccines Market, Revenues & Volume, By Technology, 2021 - 2031 |
7.2.1 United States (US) Vaccines Market, Revenues & Volume, By Technology, 2021 - 2031 |
7.2.2 Canada Vaccines Market, Revenues & Volume, By Technology, 2021 - 2031 |
7.2.3 Rest of North America Vaccines Market, Revenues & Volume, By Technology, 2021 - 2031 |
7.3 North America Vaccines Market Revenues & Volume Share, By Type, 2021 & 2031F |
7.3.1 United States (US) Vaccines Market, Revenues & Volume, By Type, 2021 - 2031 |
7.3.2 Canada Vaccines Market, Revenues & Volume, By Type, 2021 - 2031 |
7.3.3 Rest of North America Vaccines Market, Revenues & Volume, By Type, 2021 - 2031 |
7.4 North America Vaccines Market, Revenues & Volume, By Disease Indication, 2021 - 2031 |
7.4.1 United States (US) Vaccines Market, Revenues & Volume, By Disease Indication, 2021 - 2031 |
7.4.2 Canada Vaccines Market, Revenues & Volume, By Disease Indication, 2021 - 2031 |
7.4.3 Rest of North America Vaccines Market, Revenues & Volume, By Disease Indication, 2021 - 2031 |
7.5 North America Vaccines Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
7.5.1 United States (US) Vaccines Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
7.5.2 Canada Vaccines Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
7.5.3 Rest of North America Vaccines Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
7.6 North America Vaccines Market, Revenues & Volume, By Patient Type, 2021 - 2031 |
7.6.1 United States (US) Vaccines Market, Revenues & Volume, By Patient Type, 2021 - 2031 |
7.6.2 Canada Vaccines Market, Revenues & Volume, By Patient Type, 2021 - 2031 |
7.6.3 Rest of North America Vaccines Market, Revenues & Volume, By Patient Type, 2021 - 2031 |
8 North America Vaccines Market Key Performance Indicators |
9 North America Vaccines Market - Export/Import By Countries Assessment |
10 North America Vaccines Market - Opportunity Assessment |
10.1 North America Vaccines Market Opportunity Assessment, By Countries, 2021 & 2031F |
10.2 North America Vaccines Market Opportunity Assessment, By Technology, 2021 & 2031F |
10.3 North America Vaccines Market Opportunity Assessment, By Type, 2021 & 2031F |
10.4 North America Vaccines Market Opportunity Assessment, By Disease Indication, 2021 & 2031F |
10.5 North America Vaccines Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
10.6 North America Vaccines Market Opportunity Assessment, By Patient Type, 2021 & 2031F |
11 North America Vaccines Market - Competitive Landscape |
11.1 North America Vaccines Market Revenue Share, By Companies, 2022 |
11.2 North America Vaccines Market Competitive Benchmarking, By Operating and Technical Parameters |
12 Top 10 Company Profiles |
13 Recommendations |
14 Disclaimer |